Since its discovery in 1986 nuclear factor kappa B attracted attention of scientists all over the world. Intensive
research has proved its indisputable role in pathogenesis of particularly inflammatory and tumor diseases and revealed
many possibilities in the modulation of its function. For some of the modulators distinct therapeutic effects háve
been proved in in vitro and in vivo studies oř even in the clinical trials, some of them are still to be tested. One may
expect wide use of different inhibitors oř modulators of nuclear factor kappa B in various indications, which will
markedly enhance the therapeutic effect
apoptosis, nuclear factor kappa B, tumorigenesis, tumors, therapy, inflammation.